Intellectual Property

CellMDx, Inc., the parent company of OncoCell MDx, Inc., has amassed a broad IP portfolio, including rights (from Harvard University) to 39 issued patents and more than 100 pending applications in the United States and internationally. These issued and pending patents cover various aspects of the SNEP technology in numerous clinical indications including cancer, cardiovascular, infectious, and neurodegenerative disease, and immune- and kidney-related diseases.